-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Antiviral agent 52
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/101784-44-52d.gif)
Category | Hepatitis C Virus (HCV) |
CAS | 101784-44-5 |
Description | Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). It is a blood-borne virus, which can cause both acute and chronic hepatitis. CAY10704 is a potent inhibitor of hepatitis C virus (HCV) infection with EC50 of 17 nM. It displays good pharmacokinetics in mice with preferential liver distribution without significant hepatotoxicity. CAY10704 is also selective for HCV over dengue virus with EC50 of 4.62 µM. |
Product Information
Synonyms | 101784-44-5;1-(Bis(4-chlorophenyl)methyl)-4-methylpiperazine;Antiviral agent 52;1-[bis(4-chlorophenyl)methyl]-4-methylpiperazine;1-[bis(4-chlorophenyl)methyl]-4-methyl-piperazine;CAY10704;SCHEMBL2056217;CHEMBL3771316;BEA78444;AKOS040755846;HY-113860;CS-0062963; |
IUPAC Name | 1-[bis(4-chlorophenyl)methyl]-4-methylpiperazine |
Molecular Weight | 335.27 |
Molecular Formula | C18H20Cl2N2 |
Canonical SMILES | CN1CCN(C(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)CC1 |
InChI | InChI=1S/C18H20Cl2N2/c1-21-10-12-22(13-11-21)18(14-2-6-16(19)7-3-14)15-4-8-17(20)9-5-15/h2-9,18H,10-13H2,1H3 |
InChIKey | UVQVBDRHJUMBET-UHFFFAOYSA-N |
Purity | ≥98% |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |